All News

RheumNow Podcast square

Best of 2022: EULAR 2022 Top 10 Abstracts

Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…

Read Article
RheumNow Podcast square

Fever, FROST, & Pericarditis (12.16.2022)

Jack Cush, MD

Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK".

Read Article
hidradenitis.jpg

Inflammatory Arthritis and Hidradenitis Suppurativa

Jack Cush, MD

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Jack Cush, MD

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Read Article
ACR meeting education

ACR22 Takeaways: Pre-RA, Lupus, PsA and AS

Robert Chao, MD

ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways. 

Read Article
scale decision balance question

The disconnect between objective inflammatory response and PROs in AxSpA

Antoni Chan, MD, PhD

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment.

Read Article
together solution

A Multidimensional Approach in the Management of Axial Spondylarthritis

Akhil Sood, MD

There has been much focus on the pharmacologic management of axSpA. Despite optimal control of inflammation, symptoms of fatigue and pain can persist. Long term use of analgesics including opioids carries significant risks. Strategies to improve response to treatment in this population is critical.

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Jack Cush, MD

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 



I loved the city, but not the convention center (not easy to navigate). 

Read Article
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb

Links:

Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/Kc1n4RVe3v

Links:

Dr. John Cush RheumNow ( View Tweet)

The First Head to Head trial in Axial SpA Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H

Links:

Dr. John Cush RheumNow ( View Tweet)
Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. https://t.co/dCLlgiGV9K https://t.co/a4iI1q3zZC

Links:

Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI

Links:

Dr. John Cush RheumNow ( View Tweet)
A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis. https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo

Links:

Dr. John Cush RheumNow ( View Tweet)
Lifestyle Modifications may enhance TNF Inhibitors in axSpA https://t.co/0O4jd3g0WL https://t.co/zUaRUR9tGL

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Topic Panel - #ACR22 SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims @synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims https://t.co/uFPW3NxZEm https://t.co/stjmhcFoaS

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA from #ACR22. -Abstract 0402 -Abstract 0388 -Abstract 0544 -Abstract 0545 https://t.co/1PvN3SnqHQ https://t.co/i2nyvjyv3D

Links:

Dr. John Cush RheumNow ( View Tweet)
TNFi cycling in axSpA: Results from CorEVITAS Registy study Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presented at #ACR22. https://t.co/rvzB2RHkAD https://t.co/m3uiXAvZmZ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×